1B1.F ONCOARENDI THERAP ZY-01

Healthcare Biotechnology Frankfurt Exchange
1.18 EUR
Close of Nov 11, 2026
1.15 2.02
Market cap
EUR 29.2M
P/E
-
P/B
1.43x
ROE
-21.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2025.

Is 1B1.F undervalued?

Graham number

The Graham number of ONCOARENDI THERAP ZY-01 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ONCOARENDI THERAP ZY-01 fundamental analysis

No fundamental analysis for ONCOARENDI THERAP ZY-01 yet.

ONCOARENDI THERAP ZY-01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ONCOARENDI THERAP ZY-01

Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Pha…

Full company profile